Medical Device Microscopic Polyangiitis Market Modest Situation | Page 2

REPORT DESCRIPTION
Microscopic Polyangiitis Market – Overview
Launch of new treatment methods by key players is expected to drive the global microscopic polyangiitis
market growth over the forecast period. For instance, in July 2018, InflaRx N.V., a German clinical stage
bio-pharmaceutical company, received an approval from the U.S. Food and Drug Administration (FDA) for
conducting phase-2 clinical trials to assess the safety and effectiveness of IFX-1 for treatment of anti-
neutrophil cytoplasmic autoantibody (ANCA) vasculitis, presence of which indicates that the patient is
suffering from microscopic polyangiitis. IFX-1 is an inhibitor of the complement system (a component of
immune system) and neutralizes C5a component without affecting the normal immune functions. These
factors are expected to drive the global microscopic polyangiitis market growth over the forecast period.
The corticosteroids have side effects, which include skin thinning and intense pain. The monoclonal
antibody production involves costly and time consuming research. Azathioprine involves side effects such
as diarrhea, joint pain, loss of coordination, seizure, and vision changes. These factors are expected to
restrain the global microscopic polyangiitis market growth over the forecast period.